A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma

J Clin Endocrinol Metab. 2005 May;90(5):2831-4. doi: 10.1210/jc.2004-2139. Epub 2005 Feb 15.

Abstract

This study represents the first report of gene therapy for anaplastic thyroid carcinoma, one of the most aggressive solid tumors in humans. Two patients with end-stage anaplastic thyroid carcinoma were treated by direct intratumor injection of retroviral vector producer cells followed by ganciclovir. The retroviral vector carried the human IL-2 gene and the suicide gene thymidine kinase of herpes simplex virus type 1. Treatment was safe and associated with only mild adverse events. Transduction of tumor cells and production of T helper type 1 cytokines was demonstrated in tumor biopsies. Gene therapy led also to a marked increase in T helper type 1 cytokine expression in peripheral blood mononuclear cells. Radiological evaluation of injected tumor masses demonstrated local tumor necrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Carcinoma / therapy*
  • Cytokines / genetics*
  • Female
  • Ganciclovir / therapeutic use
  • Genetic Therapy*
  • Humans
  • Pilot Projects
  • Retroviridae / genetics
  • Thymidine Kinase / genetics*
  • Thyroid Neoplasms / therapy*

Substances

  • Cytokines
  • Thymidine Kinase
  • Ganciclovir